Study to Evaluate the Safety and Immunogenicity of MEDI-517P in Healthy Adult Female Volunteers Who Are HPV-16 or HPV-18 DNA Positive
The primary objective of this study is to describe the safety of 40 mg MEDI-517, with a control of aluminum hydroxide, when given to healthy adult women who have evidence of HPV-16 and/or HPV-18 DNA detected in cervical brushings.
|Study Design:||Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Prevention
|Official Title:||A Phase I/II Study to Evaluate the Safety and Immunogenicity of MEDI-517, a Virus-Like Particle Vaccine Against Human Papillomavirus (HPV) Types 16 and 18, in Healthy Adult Female Volunteers Who Are HPV-16 or HPV-18 DNA Positive|
- Evaluation of safety in terms of unsolicited adverse events and serious adverse events. [ Time Frame: 7 days after each injection ] [ Designated as safety issue: Yes ]
- Determine the effect of MEDI-517 compared to aluminum hydroxide control on the proportion of volunteers who are positive for HPV DNA. [ Time Frame: Swab taken on Study Day 210 ] [ Designated as safety issue: No ]
|Study Start Date:||November 1999|
|Study Completion Date:||June 2001|
|Primary Completion Date:||April 2001 (Final data collection date for primary outcome measure)|
Biological: MEDI 517
Vaccine is supplied in single use vials containing 0.75 mL of MEDI-517 at a concentration of 40 mg/0.5 mL formulated with SBAS4 adjuvant.
Active Comparator: 2
Other: Aluminum hydroxide
Aluminum hydroxide supplied in single use vials containing 0.75 mL of aluminum hydroxide at a concentration of 0.5 mg of aluminum in the form of aluminum hydroxide per 0.5 mL.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00263744
|Study Director:||Genevieve Losonsky, M.D.||MedImmune LLC|